Dysfunctional uterine bleeding (DUB).
Cyclic or irregular uterine bleeding is common in perimenarchal and perimenopausal women with or without endometrial hyperplasia. The disturbance often requires surgical treatment because of its negative effects on both blood loss and abnormal endometrial growth including the development of endometrial cancer. The endometrium is often overstimulated during the perimenopausal period when estrogen/progesterone production is unbalanced. A therapeutical approach with gonadotropin-releasing hormone agonist (GnRHa) was proposed in a depot formulation (Zoladex) that induces a sustained and reversible ovarian suppression. To avoid the risk of osteoporosis and to obtain adequate endometrial proliferation and differentiation during ovarian suppression, transdermal 17-beta-estradiol and oral progestin were administered. Results of 20 cases versus 20 controls showed a reduction of metrorrhagia, a normalization of hemoglobin plasma concentration, and an adequate proliferation and secretory differentiation of the endometrium of patients with abnormal endometrial growth. Abnormal uterine bleeding is mainly due to uterine fibrosis and an inadequate estrogen and/or progesterone production or to a disordered estrogen transport from blood into the endometrium. In premenopausal women, endometrial hyperplasia may be part of a continuum that is ultimately manifested in the histological and biological pattern of endometrial carcinoma. The regression of endometrial hyperplasia obtained by using the therapeutic regimen mentioned above represents a preventive measure for endometrial cancer. Finally the normalization of blood loss offers a good medical alternative to surgery for patients with DUB.
Department of Obstetrics and Gynecology, University of Bologna, Italy.
C
C
Bulletti
C
C
Flamigni
R A
RA
Prefetto
V
V
Polli
E
E
Giacomucci
D000328:Adult; D003692:Delayed-Action Preparations; D004714:Endometrial Hyperplasia / Q000378:metabolism / Q000473:pathology; D004717:Endometrium / Q000737:chemistry / Q000473:pathology; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007797:Laminin / Q000032:analysis; D007986:Luteinizing Hormone / Q000097:blood; D008796:Metrorrhagia / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D011374:Progesterone / Q000097:blood
D003692:Delayed-Action Preparations; D007797:Laminin; D017273:Goserelin; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone